Cargando…

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion

background: IDH mutant astrocytoma has good prognosis compared with IDH wildtype one. In IDH mutant astrocytoma, However, patients with CDKN2A/B homozygous deletion (HD) are worse prognosis than non CDKN2A/B HD. Here we analyzed the prognosis of glioma patients identified with CDKN2A/B HD in our hos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yanagisawa, Shunsuke, Satomi, Kaishi, Miyakita, Yasuji, Ohno, Makoto, Takahashi, Masamichi, Tamura, Yukie, Kawachi, Daisuke, Kikuchi, Miyu, Kitahara, Mai, Matushita, Yuko, Yoshida, Akihiko, Ichimura, Koichi, Narita, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648235/ http://dx.doi.org/10.1093/noajnl/vdab159.064

Ejemplares similares

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma
por: Ohno, Makoto, et al.
Publicado: (2022)

STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
por: Ohno, Makoto, et al.
Publicado: (2021)

Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence
por: Kawauchi, Daisuke, et al.
Publicado: (2023)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

MPC-1 DNA methylome analysis suggested the presence of “true” IDH-wildtype lower-grade gliomas
por: Satomi, Kaishi, et al.
Publicado: (2021)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment
por: Kikuchi, Miyu, et al.
Publicado: (2021)

A rare case of brain metastasis from poorly differentiated small bowel adenocarcinoma
por: Yamazawa, Erika, et al.
Publicado: (2019)

Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas
por: Omura, Takaki, et al.
Publicado: (2022)

Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

MPC-07 MECHANISMS OF BETTER PROGNOSIS IN IDH-MUTATED ASTROCYTOMA WITH 19Q-LOSS
por: Otani, Ryohei, et al.
Publicado: (2019)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

MPC-11 Comprehensive gene expression analysis of IDH-mutated astrocytomas with 19q-loss
por: Otani, Ryohei, et al.
Publicado: (2020)

Combination of asleep and awake craniotomy as a novel strategy for resection in patients with butterfly glioblastoma: Two case reports
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Homozygous deletion of CDKN2A by fluorescence in situ hybridization is prognostic in grade 4, but not grade 2 or 3, IDH-mutant astrocytomas
por: Marker, Daniel F., et al.
Publicado: (2020)

NQPC-14 COMPARISON OF QOL SCALES IN PATIENTS WITH BRAIN TUMORS
por: Satomi, Natsuko Tsushita, et al.
Publicado: (2019)

Early Diagnosis and Surgical Intervention Within 3 Weeks From Symptom Onset Are Associated With Prolonged Survival of Patients With Glioblastoma
por: Kawauchi, Daisuke, et al.
Publicado: (2022)

NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA
por: Omura, Tomoko, et al.
Publicado: (2019)

COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF
por: Omura, Takaki, et al.
Publicado: (2019)

CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review
por: Yuile, Alexander, et al.
Publicado: (2023)

RT-5 Boron Neutron Capture Therapy has extended progression-free survival about recurrent malignant peripheral nerve sheath tumor - A case report
por: Watanabe, Yuko, et al.
Publicado: (2021)

NQPC-13 THE EFFICACY OF RAVEN’S COLORED PROGRESSIVE MATRICES FOR PATIENTS WITH BRAIN TUMOR
por: Yahiro, Sachiko, et al.
Publicado: (2019)

Impact of Inversion Time for FLAIR Acquisition on the T2-FLAIR Mismatch Detectability for IDH-Mutant, Non-CODEL Astrocytomas
por: Kinoshita, Manabu, et al.
Publicado: (2021)

NQPC-10 IMPACT OF HEALTH-RELATED QOL (HRQOL) IN THE FIRST SIX MONTHS AFTER SURGERY ON LONG-TERM POSTOPERATIVE GENERAL HEALTH STATUS IN GLIOMA PATIENTS
por: Kugasawa, Kazuha, et al.
Publicado: (2022)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

MET-10 A SINGLE CENTER RETROSPECTIVE ANALYSIS OF AWAKE CRANIOTOMY FOR METASTATIC BRAIN TUMOR
por: Yanagisawa, Shunsuke, et al.
Publicado: (2022)

Impact of CDKN2A/B Homozygous Deletion on the Prognosis and Biology of IDH-Mutant Glioma
por: Huang, L. Eric
Publicado: (2022)

COT-04 FAMILY SUPPORT FOR PATIENTS WITH PRIMARY MALIGNANT BRAIN TUMORS BY PATIENT SUPPORT GROUP IN NATIONAL CANCER CENTER
por: Horikawa, Mayumi, et al.
Publicado: (2019)

CDKN2A/B mutations and allele-specific alterations stratify survival outcomes in IDH-mutant astrocytomas
por: Hickman, Richard A., et al.
Publicado: (2023)

The ALK inhibitors, alectinib and ceritinib, induce ALK‐independent and STAT3‐dependent glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2021)

MPC-05 TUMOR RELATED EPILEPSY AND IDH MUTATIONS IN GLIOMAS
por: Wakabayashi, Hikaru, et al.
Publicado: (2019)

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies
por: Ohno, Makoto, et al.
Publicado: (2022)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

COT-15 LITERATURE REVIEW ON THE DECISION MAKING OF THE BRAIN TUMOR PATIENT
por: Kishi, Tatsuya, et al.
Publicado: (2019)

Genetic alterations that deregulate RB and PDGFRA signaling pathways drive tumor progression in IDH2-mutant astrocytoma
por: Tateishi, Kensuke, et al.
Publicado: (2023)

Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma
por: Ohno, Makoto, et al.
Publicado: (2019)

MPC-01 PROGNOSTIC ROLE OF TERT PROMOTER IMPROVES THE STRATIFICATION OF IDH-MUTATED LOWER GRADE GLIOMA
por: Arita, Hideyuki, et al.
Publicado: (2019)

INTRAVASCULAR LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM PRESENTING AS MULTIPLE CEREBRAL INFARCTIONS
por: MOMOTA, HIROYUKI, et al.
Publicado: (2012)

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas
por: Natsume, Atsushi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_snvbh6ptt9214ado11n9sg1pua